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Abstract 
Introduction: Esophageal cancer portends a poor prognosis due to high risk of recurrence, even following treatment 
with curative intent. Recurrence often occurs as distant metastasis, commonly in liver, lung, bone and brain with 
bone marrow metastasis being infrequently cited in medical literature. Herein we describe a case of bone marrow 
metastasis of an esophageal primary following resection.  
Case presentation: A 78 year-old male with locally advanced GEJ cancer who underwent chemotherapy followed 
by surgical resection with complete pathological response presented 6 weeks later with right lower quadrant pain. He 
was found to have hemorrhage in right perinephric space secondary to a ruptured kidney cyst with labs suggestive of 
DIC and hemolytic anemia. Patient was transfused multiple units of FFP, cryoprecipitate, and blood and ultimately 
required coil embolization of the right renal artery. The patient was discharged home after prolonged hospital course, 
and was found to have persistent pancytopenia with hypofibrinoginemia. Bone marrow aspirate and biopsy were 
performed, which revealed a necrotic marrow replaced with signet ring adenocarcinoma consistent with his 
esophageal primary. Patient requested hospice care and died six weeks later.  
Conclusion: Recurrence of esophageal cancer is common and can occur locoregionally or as distant metastasis, 
however bone marrow as a site of metastatic spread occurs infrequently. Esophageal cancer recurs typically within 
two years of resection, therefore follow up and surveillance is a vital component of management, keeping in mind 
that bone marrow is a possible though atypical site of recurrence.  
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Introduction  
Esophageal cancer is known to have high rates of recurrence and distant metastasis, even following 
resection with common sites including liver, lung, bone, and brain. Cases of metastatic spread of 
esophageal cancer to bone marrow are rare and infrequently cited in medical literature. We report one 
such case, which presented as persistent DIC prompting a bone marrow biopsy.  
Case Report  
We present a case of a 78 year-old male patient who initially was diagnosed with a locally advanced 
GEJ cancer in April of 2017. He underwent chemotherapy with carboplatin and Taxol for four doses 
with suboptimal response, which was followed by modified FOLFOX with proton therapy, which he 
completed in July of 2017. He underwent surgical resection in September of 2017 with a complete 
pathological response in the primary and 1 out of 21 positive lymph nodes. He presented 6 weeks later 
to a local hospital with severe right lower quadrant pain and was found to have hemorrhage in right 
perinephric space. This was thought to be secondary to a ruptured kidney cyst as the patient had a 
history of multiple large kidney cysts. He was also found to have laboratory evidence of DIC with 
decreased fibrinogen levels of 55 mg/dL, increased PT of 19.9 s, increased D-dimer of 3700 μg/mL 
and increased fibrin split products >40 μg/mL. Hemolytic anemia was also suspected due to increased 
LDH levels, decreased haptoglobin levels and persistent anemia. The patient was admitted to the ICU 
for further monitoring and was transfused multiple units of FFP and cryoprecipitate as well as blood. 
He ultimately required a coil embolization of the right renal artery due to persistent anemia and blood 
product requirement. Additional imaging revealed a giant hemangioma in the liver, which was chronic 
with no evidence of metastatic disease on imaging. 
 The patient had a prolonged hospital course, which was complicated by an acute CVA, 
which was medically managed. TPA could not be administered due to ongoing intra-abdominal 
hemorrhage and DIC. The etiology was thought to be related to either DIC with prothrombotic 
condition despite INR in the 2-range or lone atrial fibrillation. Patient had persistent pancytopenia with 
hypofibrinoginemia although the exact cause of his low grade DIC remained unclear. He ultimately 
was stabilized and discharged home. Due to persistent and worsening pancytopenia and persistent 
evidence of DIC a bone marrow aspirate and biopsy was performed. The histologic sections revealed 
extensive replacement of the marrow space by a poorly differentiated adenocarcinoma, which was 
confirmed by immunohistochemical analysis for AE1/3, with signet ring cell features.  Morphological 
comparison with the initial tumor revealed cytomorphologic features in keeping with the previously 
established esophageal adenocarcinoma primary. The patient requested hospice care and died six 
weeks later. 
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Figure 1 A. H&E staining of marrow reveals metastatic adenocarcinoma, poorly differentiated, with mucinous 
and signet ring morphology (arrow) with tumor necrosis and markedly decreased marrow reserve. B. 
Immunoperoxidase stains reveal that almost entire marrow is diffusely positive for cytokeratin AE1/AE3 
including areas of necrosis indicating extensive involvement by metastatic adenocarcinoma. 
Discussion 
Esophageal cancer is the 11th leading cause of cancer death with a 5-year survival rate of 18.8%, 
however in patients with distant metastasis, this number decreases to 4.6% [1]. The poor prognosis of 
this malignancy can be attributed to the high rates of recurrence and metastatic spread. One study 
noted that 38% of cases experience recurrent disease with distant metastasis occurring in 55% of 
recurrences, locoregional spread in 28% of cases, and 17% of cases with both [2], In this case of early 
recurrence with distant metastases to bone marrow, survival was less than six months following 
surgical resection.  
 Recurrence is estimated to occur in approximately 38% of cases of esophageal cancer, 
including squamous cell carcinoma or adenocarcinoma. The median time to recurrence of esophageal 
cancer is 5.5 years, however among these cases 75% of recurrences occurred within the first two years 
after surgery, which is consistent with our case of rapid recurrence only 6 weeks following surgical 
resection with complete pathological response.2 Most common sites of metastatic spread include liver, 
lymph nodes, lung, bone, and brain, with metastatic spread to bone offering the poorest prognosis [3].. 
Esophageal adenocarcinoma, as in our case, is noted to be almost twice as likely to have metastasized 
at time of diagnosis than esophageal squamous cell carcinoma [4]. 
 Though bone marrow involvement has been reported as micrometastasis, no known cases of 
metastatic invasion of bone marrow by esophageal cancer have been reported in medical literature. 
Micrometastases are small collections of tumor cells that have spread from the primary tumor and are 
able to evade detection with imaging studies. Presence of micrometastasis has been associated with 
tumors of poorer histological grade [5], lymphovascular invasion, and advanced T-stage [6], though 
reports on the effect of bone marrow micrometastasis vary with regard to overall survival [6-8]. 
 Several case reports documenting metastatic spread of gastric cancer to bone marrow exist in 
medical literature, including the ones mentioned in the table below [9-11]. One such case had a 
  
 
Martin  JL et al.American Journal of Cancer Case Reports 2018, 6:31-35                                                                        Page 4 of 5 
Ivy Union Publishing | http: //www.ivyunion.org                                                                         September 26, 2018 | Volume 6, Issue 1 
 
remarkably similar presentation to our case, in which the patient presented with a clinically significant 
bleed (epistaxis) and was subsequently found to have DIC. However only one case has been found 
describing esophageal cancer as a primary source of bone marrow carcinomatosis, in which case the 
primary neoplasm was an esophageal squamous cell carcinoma [12]. In these cases that have been 
previously reported, survival was limited to a few weeks at best.  
 
Table 1 Existing reports of gastric and esophageal cancer with bone marrow metastasis 
 
Author Primary neoplasm Previous treatment  Presenting 
symptoms 
Other 
Seki, Y. et 
al 2016 [9]  
Mucin-producing gastric 
adenocarcinoma at GE 
junction, previously 
undiagnosed 
None Epistaxis, found 
to have DIC 
Patient expired on 
hospital day 3 
Fonocho, E. 
et al 2017 
[10] 
Non-metastatic gastric 
adenocarcinoma in antrum 
of stomach 
Roux-en-Y 
gastrojejunostomy two years 
prior 
Pancytopenia Also had bone 
metastases. Underwent 
palliative chemotherapy 
Chen, Y. et 
al 2014 [12] 
Esophageal squamous cell 
carcinoma with metastatic 
disease to liver and bone 
Chemoradiotherapy with 
cisplatin/5-fluorouracil 
Headache, 
diplopia, hearing 
impairment 
Found to have dural 
metastasis on MRI in 
addition to BM 
metastasis on BM biopsy 
Ekinci, A.S. 
et al 2014 
[11] 
5 cases of gastric 
adenocardinoma, 4 in the 
corpus, 1 in the cardia 
One patient had previous 
curative surgery with 
adjuvant chemoradiotherapy.  
 
Others had no previous 
treatment 
Various 
cytopenias 
Range of survival 20-53 
days in 4/5 patients 
deceased at time of 
publication 
 
 Many case reports exist documenting DIC as a complication of bone marrow 
carcinomatosis. DIC is also a common complication of malignancy, specifically solid tumors.  
DIC in cancer has, in general, a less fulminant presentation than the types of DIC 
complicating sepsis and trauma [13]. This process is mediated by tissue factor expression by 
tumor cells in addition to other procoagulant molecules, a process which is promoted by pro-
inflammatory cytokines. Additionally, most tumors induce a hypofibrinolytic state promoting 
DIC. Chemotherapy can also increase risk of developing thrombosis due to damaging effects 
to endothelium  [13]. DIC is more commonly associated with adenocarcinoma than other tumor 
types, and the tumors typically originate in the GI tract, pancreas, lung, breast, or prostate  [14].  
 In conclusion, no existing literature exists to our knowledge of metastatic esophageal 
adenocarcinoma leading to bone marrow carcinomatosis, though rare reports exist of this 
pattern of metastasis in gastric cancer. Both gastric and esophageal cancer have high rates of 
recurrence and require enhanced surveillance following treatment.  
Consent 
Written informed consent was obtained from the patient’s wife for publication of this case 
report and any accompanying images. A copy of the written consent is available for review by 
the Editor-in-Chief of this journal. 
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